Guilhem Chaubet, from the BFC team, is the recipient of a 2025 ERC Consolidator Grant for his research project entitled MuSyc. Congratulations Guilhem!!!
In his MuSyC project, Guilhem Chaubet is studying antibody-drug conjugates (ADCs), a recent class of anticancer agents with strong therapeutic potential.
Composed of an antibody that selectively recognizes cancer cells and to which a cytotoxic compound has been grafted—conjugated—, ADCs are capable of triggering the targeted destruction of cancer cells, unlike conventional chemotherapies.
Although a dozen ADCs are already used in therapy, their production remains extremely expensive and time-consuming, and their structural diversity is limited. This constitutes a major obstacle to innovation in this still-developing field, preventing the emergence of next-generation ADCs.
To overcome these challenges, the MuSyC project is developing a new chemical approach to ADC production using multicomponent reactions. These reactions will enable the synthesis and conjugation of new compounds of interest to antibodies, increasing the structural diversity of ADCs while accelerating their production. At the interface between chemistry and biology, the MuSyC project aims to develop new generations of antibody-based targeted therapies.
[Source: press release of CNRS Alsace]
